Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.
Wayne P GulliverMelinda J GooderhamBaojin ZhuChristian JossartSonia MontmayeurRussel T BurgeCatherine ReedPublished in: Dermatology and therapy (2022)
Patients with moderate-to-severe PsO overwhelmingly remained on ixekizumab treatment for more than 2 years while participating in a PSP.